Although there is no direct evidence that the liver function improves when SGLT2 is administered to patients with cirrhosis, SGLT2 inhibitors may have improved the liver function in the examined cirrhotic patients by improving glucose metabolism. The gene discussed is SLC5A2; the disease is Cirrhosis.